Speaker "Armen Kherlopian" Details Back



Medical Natural Language Processing and Machine Learning for Drug Safety


At the heart of drug safety is a question: do the benefits of a particular medicine outweigh its risks? During this talk, Dr. Armen Kherlopian will discuss how advanced technologies such as Natural Language Processing and Machine Learning are being leveraged to continually monitor for adverse drug events. The talk will also touch on additional supporting technology areas such as Computational Linguistics, Graph Analytics, Computer Vision and domain-specific Ontology creation as to form an Artificial Intelligence based system for Pharmacovigilance, the area of drug safety concerned with post-marketing surveillance of medical products. As articulated by Dr. Kherlopian, by integrating Artificial Intelligence across the information value chain in a non-black box fashion, it’s possible to enable a virtuous circle of improving data quality and insight all while maintaining strict regulatory standards.


Dr. Armen Kherlopian serves as Chief Science Officer at Genpact and has provided high impact Data Science advisory for Global Fortune 100 companies and government organizations such as NASA. He is a co-founder of the Data Science Bowl, the largest data challenge for social good, and a co-author of the Field Guide to Data Science, which has over 25,000 copies in distribution. Also, Dr. Kherlopian is an awardee of the U.S. National Science Foundation Graduate Research Fellowship, U.S. Department of Energy Computational Science Graduate Fellowship, and is a U.S. delegate to the Lindau Nobel Laureates Meetings in Germany. He holds a BS and MS in Biomedical Engineering with a focus on Algorithms from Columbia University, a PhD in Biophysics with a focus on Machine Learning from Cornell University, and completed a fellowship in High Performance Computing with a focus on Artificial Intelligence at Princeton University. Genpact (NYSE: G) is a global technology and professional services firm focusing on transformation, and was spun out of GE (NYSE: GE) maintaining a strong heritage of Six Sigma for process improvement. With over 75,000 staff in 20 countries, Genpact drives digital-led innovation and digitally-enabled intelligent operations for clients, guided by experience in running thousands of processes for hundreds of Global Fortune 500 companies. The Genpact Chief Science Office (CSO) works with internal and external organizations to drive industry leading capabilities to accelerate analytic maturity for clients, starting with digitization and progressing through Robotic Process Automation, Advanced Analytics, Machine Learning and to Artificial Intelligence. Bringing to bear the latest algorithms, each CSO staff member is a senior thought leader that collaborates with Genpact’s select client partners to engage in dialogue, exchange ideas, and advance the art of the possible.